It could be assumed that susceptibility to VEGF inhibitor in patients with NSCLC and liver metastases arises from a reversal of immune suppression by VEGF inhibitor, which basically reduces the infiltration of CD8+ T cells, which may further enhance the T cell-mediated killing of cancer cells by PD-L1 inhibitor [57]. Here, VEGFA is linked to non-small cell lung carcinoma.